• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).

作者信息

Martin-Blondel Guillaume, Marcelin Anne-Genevieve, Soulié Cathia, Kaisaridi Sofia, Lusivika-Nzinga Clovis, Dorival Céline, Nailler Laura, Boston Anaïs, Melenotte Cléa, Gaube Géraldine, Choquet Christophe, Liblau Roland, Carrat Fabrice, Yordanov Youri

机构信息

Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, France.

Sorbonne Université, INSERM, Laboratoire de Virologie, AP-HP, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Paris, France.

出版信息

J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7.

DOI:10.1016/j.jinf.2022.04.010
PMID:35398409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8988484/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad8/8988484/4eac45df5d12/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad8/8988484/4eac45df5d12/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cad8/8988484/4eac45df5d12/gr1_lrg.jpg

相似文献

1
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).索托维单抗治疗轻至中度新冠病毒奥密克戎变异株感染的极高风险患者的结局：一项前瞻性队列研究（法国国家艾滋病研究机构0003S COCOPREV研究）
J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7.
2
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.奥密克戎 BA.1 和 BA.2 轻症和中症 COVID-19 高风险患者接受 sotrovimab 或 nirmatrelvir 治疗后，PCR 转为阴性的时间。
Clin Microbiol Infect. 2023 Apr;29(4):543.e5-543.e9. doi: 10.1016/j.cmi.2022.12.016. Epub 2022 Dec 28.
3
[Sotrovimab in controlling SARS-CoV-2 infection].[索托维单抗在控制新型冠状病毒2感染中的作用]
Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50.
4
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.贝特洛维单抗和索特罗维单抗治疗奥密克戎纪元中 COVID-19 轻症至中症的实体器官移植受者的结局。
Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25.
5
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.奥密克戎 BA.1 流行期间，高风险轻至中度 COVID-19 门诊患者使用瑞德西韦和索特罗维单抗的可比结局。
Sci Rep. 2024 Mar 5;14(1):5430. doi: 10.1038/s41598-024-56195-y.
6
Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.在奥密克戎时代，用于接种疫苗或未接种疫苗的 COVID-19 轻症至中度患者的 sotrovimab 的疗效和安全性。
Drug Discov Ther. 2022 Jul 20;16(3):124-127. doi: 10.5582/ddt.2022.01036. Epub 2022 Jun 25.
7
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.索特罗维单抗对伴有轻度至中度 COVID-19 的高危患者住院或死亡的影响：一项随机临床试验。
JAMA. 2022 Apr 5;327(13):1236-1246. doi: 10.1001/jama.2022.2832.
8
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.比利时使用 sotrovimab 治疗以预防 COVID-19 进展为重症的患者的特征和结局。
Acta Clin Belg. 2024 Jun;79(3):174-183. doi: 10.1080/17843286.2024.2381272. Epub 2024 Jul 31.
9
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.针对严重急性呼吸综合征冠状病毒 2 株 delta 和 omicron 变异株的单克隆抗体的临床疗效和体外中和能力。
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
10
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.在英格兰国民保健服务体系（NHS）医院中，推测接受索托维单抗治疗的新冠病毒疾病（COVID-19）患者的特征及治疗结果
BMC Infect Dis. 2024 Apr 22;24(1):428. doi: 10.1186/s12879-024-09311-2.

引用本文的文献

1
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.提高免疫缺陷患者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性免疫的策略概述
Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675.
2
Use of Monoclonal Antibodies in Pregnant Women Infected by COVID-19: A Case Series.新型冠状病毒肺炎感染孕妇中单克隆抗体的应用：病例系列
Microorganisms. 2023 Jul 31;11(8):1953. doi: 10.3390/microorganisms11081953.
3
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England.

本文引用的文献

1
Summary for Patients: Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments.患者总结：巴黎急诊科收治的感染新冠病毒德尔塔变异株与奥密克戎变异株患者的比较
Ann Intern Med. 2022 Jun;175(6):I32. doi: 10.7326/P22-0005. Epub 2022 Mar 15.
2
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.索特罗维单抗对伴有轻度至中度 COVID-19 的高危患者住院或死亡的影响：一项随机临床试验。
JAMA. 2022 Apr 5;327(13):1236-1246. doi: 10.1001/jama.2022.2832.
3
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
比较在英格兰社区接受 sotrovimab 治疗的 BA.1 和 BA.2 COVID-19 病例住院风险。
Influenza Other Respir Viruses. 2023 May;17(5):e13150. doi: 10.1111/irv.13150.
4
Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO).Sotrovimab 治疗 COVID-19 孕妇在 BA.1 奥密克戎为主导的时代（PRESTO）的结局。
BMC Infect Dis. 2023 Apr 26;23(1):258. doi: 10.1186/s12879-023-08198-9.
5
Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.降低 SARS-CoV-2 感染的实体器官移植受者进展为重症的风险：单克隆抗体治疗的作用
Rev Esp Quimioter. 2023 Aug;36(4):380-391. doi: 10.37201/req/023.2023. Epub 2023 Apr 24.
6
[Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment].[脆弱患者的轻度新型冠状病毒2型感染：早期治疗临床路径的实施]
Enferm Infecc Microbiol Clin. 2022 Dec 6. doi: 10.1016/j.eimc.2022.11.004.
7
COVID-19 in donation and transplant.COVID-19 与捐赠和移植。
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):54-62. doi: 10.37201/req/s03.13.2022. Epub 2022 Oct 24.
8
Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections.西加维单抗/替沙格维单抗作为BA.2感染的替代治疗方法。
Front Med (Lausanne). 2022 Sep 29;9:1005589. doi: 10.3389/fmed.2022.1005589. eCollection 2022.
9
Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis.索特罗维单抗治疗 COVID-19 患者的疗效和安全性：快速综述和荟萃分析。
Rev Med Virol. 2022 Nov;32(6):e2402. doi: 10.1002/rmv.2402. Epub 2022 Oct 12.
10
Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.严重急性呼吸综合征冠状病毒 2 型奥密克戎感染免疫功能低下患者中索托维单抗逃逸变异的快速选择。
Clin Infect Dis. 2023 Feb 8;76(3):408-415. doi: 10.1093/cid/ciac802.
SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
4
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
5
The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials.中和单克隆抗体对 COVID-19 门诊患者结局的影响：一项随机对照试验的系统评价和荟萃分析。
J Med Virol. 2022 May;94(5):2222-2229. doi: 10.1002/jmv.27623. Epub 2022 Feb 7.
6
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
7
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.REGEN-COV 抗体组合在门诊 COVID-19 患者中的应用及结果。
N Engl J Med. 2021 Dec 2;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29.
8
Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people.法国第一波疫情期间慢性病、健康状况与新冠病毒相关住院及院内死亡风险：一项针对6600万人的队列研究
Lancet Reg Health Eur. 2021 Sep;8:100158. doi: 10.1016/j.lanepe.2021.100158. Epub 2021 Jul 16.
9
Nextstrain: real-time tracking of pathogen evolution.Nextstrain：实时追踪病原体进化。
Bioinformatics. 2018 Dec 1;34(23):4121-4123. doi: 10.1093/bioinformatics/bty407.